Cargando…
Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report
INTRODUCTION: Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Several novel therapeutic strategies have been developed to prolong the survival of patients with advanced HCC. However, therapeutic decision-making biomarkers owing to the extensive heterogeneity of HCC. Next-...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467267/ https://www.ncbi.nlm.nih.gov/pubmed/37655101 http://dx.doi.org/10.3389/fonc.2023.1196211 |
_version_ | 1785099078676250624 |
---|---|
author | Gu, Yangjun Xiao, Min Chen, Zhitao Li, Qiyong |
author_facet | Gu, Yangjun Xiao, Min Chen, Zhitao Li, Qiyong |
author_sort | Gu, Yangjun |
collection | PubMed |
description | INTRODUCTION: Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Several novel therapeutic strategies have been developed to prolong the survival of patients with advanced HCC. However, therapeutic decision-making biomarkers owing to the extensive heterogeneity of HCC. Next-generation sequencing (NGS) is generally used in treatment decisions to help patients benefit from genome-directed targeting. CASE PRESENTATION: A 56 year-old male with type-B hepatitis for more than 20 years was admitted to our department and underwent laparoscopic left lateral hepatic lobectomy for hepatocellular carcinoma. Unfortunately, the tumor recurred 1 year later. Despite multiple treatments, the tumor continued to progress and invaded the patient’s 5th thoracic vertebras, leading to hypoesthesia and hypokinesia below the nipple line plane 2 years later. NGS revealed MET amplification, and crizotinib, an inhibitor of MET, was recommended. After administration for a month, tumor marker levels decreased, and the tumor shrunk. The patient has remained in remission since that time. CONCLUSIONS: We report that a patient with high MET amplification benefited from its inhibitor, which was recommended by NGS. This indicates the potential clinical decision support value of NGS and the satisfactory effect of MET inhibitors. |
format | Online Article Text |
id | pubmed-10467267 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104672672023-08-31 Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report Gu, Yangjun Xiao, Min Chen, Zhitao Li, Qiyong Front Oncol Oncology INTRODUCTION: Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide. Several novel therapeutic strategies have been developed to prolong the survival of patients with advanced HCC. However, therapeutic decision-making biomarkers owing to the extensive heterogeneity of HCC. Next-generation sequencing (NGS) is generally used in treatment decisions to help patients benefit from genome-directed targeting. CASE PRESENTATION: A 56 year-old male with type-B hepatitis for more than 20 years was admitted to our department and underwent laparoscopic left lateral hepatic lobectomy for hepatocellular carcinoma. Unfortunately, the tumor recurred 1 year later. Despite multiple treatments, the tumor continued to progress and invaded the patient’s 5th thoracic vertebras, leading to hypoesthesia and hypokinesia below the nipple line plane 2 years later. NGS revealed MET amplification, and crizotinib, an inhibitor of MET, was recommended. After administration for a month, tumor marker levels decreased, and the tumor shrunk. The patient has remained in remission since that time. CONCLUSIONS: We report that a patient with high MET amplification benefited from its inhibitor, which was recommended by NGS. This indicates the potential clinical decision support value of NGS and the satisfactory effect of MET inhibitors. Frontiers Media S.A. 2023-08-16 /pmc/articles/PMC10467267/ /pubmed/37655101 http://dx.doi.org/10.3389/fonc.2023.1196211 Text en Copyright © 2023 Gu, Xiao, Chen and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Gu, Yangjun Xiao, Min Chen, Zhitao Li, Qiyong Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report |
title | Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report |
title_full | Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report |
title_fullStr | Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report |
title_full_unstemmed | Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report |
title_short | Advanced hepatocellular carcinoma with MET-amplified contained excellent response to crizotinib: a case report |
title_sort | advanced hepatocellular carcinoma with met-amplified contained excellent response to crizotinib: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467267/ https://www.ncbi.nlm.nih.gov/pubmed/37655101 http://dx.doi.org/10.3389/fonc.2023.1196211 |
work_keys_str_mv | AT guyangjun advancedhepatocellularcarcinomawithmetamplifiedcontainedexcellentresponsetocrizotinibacasereport AT xiaomin advancedhepatocellularcarcinomawithmetamplifiedcontainedexcellentresponsetocrizotinibacasereport AT chenzhitao advancedhepatocellularcarcinomawithmetamplifiedcontainedexcellentresponsetocrizotinibacasereport AT liqiyong advancedhepatocellularcarcinomawithmetamplifiedcontainedexcellentresponsetocrizotinibacasereport |